CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.3. TOP INVESTMENT POCKETS
3.4. HUMAN DNA VACCINES-KEY FACTS
3.5. REGULATION OF VACCINES BY FDA
3.6. CLINICAL TRIALS
3.7. PRICING FOR TOP GLOBAL VACCINE PRODUCTS
3.8. MARKET OPPORTUNITIES
CHAPTER 4 FORECAST SCENARIO ANALYSIS OF HUMAN DNA VACCINES MARKET
4.1. OVERVIEW
4.1.1. Market size & forecast
4.1.1.1. Rapid growth scenario
4.1.1.2. Moderate growth scenario
4.1.1.3. Low growth scenario
CHAPTER 5 GLOBAL POTENTIAL ANALYSIS OF HUMAN DNA VACCINES MARKET, BY GEOGRAPHY
5.1. OVERVIEW
5.2. NORTH AMERICA
5.2.1. Key opportunities
5.2.2. Market size & forecast
5.3. EUROPE
5.3.1. Key opportunities
5.3.2. Market size & forecast
5.4. ASIA-PACIFIC
5.4.1. Key opportunities
5.4.2. Market size & forecast
5.5. LAMEA
5.5.1. Key opportunities
5.5.2. Market size & forecast
CHAPTER 6 COMPANY PROFILES
6.1. INOVIO PHARMACEUTICALS, INC.
6.1.1. Overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Business performance
6.1.5. Product pipeline
6.1.6. Research funding
6.1.7. Key strategic developments
6.2. GENEONE LIFE SCIENCE INC.
6.2.1. Overview
6.2.2. Company snapshot
6.2.3. Operating business segments
6.2.4. Business performance
6.2.5. Product pipeline
6.2.6. Research funding
6.2.7. Key strategic developments
6.3. MEDIMMUNE
6.3.1. Overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Business performance
6.3.5. Product pipeline
6.3.6. Research funding
6.3.7. Key strategic developments
6.4. IMMUNOMIC THERAPEUTICS, INC.
6.4.1. Overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Business performance
6.4.5. Product pipeline
6.4.6. Research funding
6.4.7. Strategic moves and developments
6.5. ASTELLAS PHARMA, INC.
6.5.1. Overview
6.5.2. Company snapshot
6.5.3. Operating business segments
6.5.4. Business performance
6.5.5. Product pipeline
6.5.6. Research fuding
6.5.7. Strategic moves and developments
6.6. PHAROS BIOLOGICALS
6.6.1. Overview
6.6.2. Company snapshot
6.6.3. Operating business segments
6.6.4. Business performance
6.6.5. Product pipeline
6.6.6. Research funding
6.6.7. Strategic moves and developments
6.7. SANOFI S.A.
6.7.1. Overview
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Business performance
6.7.5. Product pipeline
6.7.6. Research funding
6.7.7. Strategic moves and developments
6.8. F. HOFFMANN-LA ROCHE AG
6.8.1. Overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Business performance
6.8.5. Product pipeline
6.8.6. Research funding
6.8.7. Strategic moves and developments
6.9. CUREVAC
6.9.1. Overview
6.9.2. Company snapshot
6.9.3. Operating business segments
6.9.4. Business performance
6.9.5. Product pipeline
6.9.6. Research fuding
6.9.7. Strategic moves and developments
6.10. BOEHRINGER INGELHEIM GMBH
6.10.1. Overview
6.10.2. Company snapshot
6.10.3. Operating business segments
6.10.4. Business performance
6.10.5. Product pipeline
6.10.6. Research funding
6.10.7. Strategic moves and developments